Maryland Capital Advisors’s Quest Diagnostics DGX Stock Holding History

Maryland Capital Advisors’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$212	Buy	+1	New	+$196	﹤0.01%	433
2023 Q4	–	Sell	-15	Closed	-$1.83K	–	234
2023 Q3	$1.83K	Hold	15	–	–	﹤0.01%	209
2023 Q2	$2.11K	Buy	+15	New	+$2.07K	﹤0.01%	216

Other funds holding DGX

AIM

Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return

Eastern Bank Boston, Massachusetts $6.53B AUM 30.05% 1-Year Est. Return

CPC

Cookson Peirce & Co Pittsburgh, Pennsylvania $3.04B AUM 94.11% 1-Year Est. Return

AIM

Achmea Investment Management Zeist, Netherlands $4B AUM 31.99% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

AAMU

AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return

AAIS

ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

BCAM

Boston Common Asset Management Boston, Massachusetts $1.69B AUM 28.29% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Maryland Capital Advisors's DGX Position: Q2 2026 in Review

Maryland Capital Advisors opened a new position in Quest Diagnostics (DGX) in Q2 2026: 1 share worth $212. The stake represents ﹤0.01% of the portfolio and ranks #433 among its holdings. This is a return to the name: Maryland Capital Advisors previously reported a position in DGX as recently as Q3 2023.

Maryland Capital Advisors first reported a position in DGX in Q2 2023 and has held it in 3 quarters since. The position peaked at $2.11K in Q2 2023. 264 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

Maryland Capital Advisors held 1 share of Quest Diagnostics worth $212 as of Q2 2026.
Quest Diagnostics was a new Maryland Capital Advisors position in Q2 2026.
Quest Diagnostics made up ﹤0.01% of Maryland Capital Advisors's portfolio in Q2 2026, its #433 holding.
Maryland Capital Advisors first reported a position in Quest Diagnostics in Q2 2023 and has held it in 3 quarters since.
Maryland Capital Advisors's Quest Diagnostics position peaked at $2.11K in Q2 2023.
264 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Maryland Capital Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.